BioMarin To Get Royalties From Ascendis Under IP Settlement
Ascendis Pharma will pay BioMarin Pharmaceutical Inc. royalties under an agreement resolving their patent disputes over competing treatments for children with a certain genetic disorder, ending proceedings at the U.S. International...To view the full article, register now.
Already a subscriber? Click here to view full article